

Christopher Sjöwall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7612358/publications.pdf>

Version: 2024-02-01

175
papers

4,281
citations

94433

37
h-index

155660

55
g-index

179
all docs

179
docs citations

179
times ranked

5690
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 1561-1568.	2.2	4
2	Comparison of treatment retention of originator <i>vs</i> biosimilar products in clinical rheumatology practice in Sweden. <i>Rheumatology</i> , 2022, 61, 3596-3605.	1.9	7
3	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. <i>RMD Open</i> , 2022, 8, e002099.	3.8	12
4	Standardisation of ACPA tests: evaluation of a new candidate reference preparation. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1379-1384.	0.9	2
5	Variation of Complement Protein Levels in Maternal Plasma and Umbilical Cord Blood during Normal Pregnancy: An Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3611.	2.4	1
6	Autoantibodies Associated with Autoimmune Liver Diseases in a Healthy Population: Evaluation of a Commercial Immunoblot Test. <i>Diagnostics</i> , 2022, 12, 1572.	2.6	1
7	Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	9
8	IgA rheumatoid factor in rheumatoid arthritis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1617-1626.	2.3	6
9	<i>De novo</i> lupus nephritis during treatment with belimumab. <i>Rheumatology</i> , 2021, 60, 4348-4354.	1.9	14
10	Contributions of de novo variants to systemic lupus erythematosus. <i>European Journal of Human Genetics</i> , 2021, 29, 184-193.	2.8	6
11	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 404-406.	0.9	7
12	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 109-117.	0.9	35
13	Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 1-10.	1.1	6
14	Case Report: <i>Borrelia</i> -DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab. <i>Frontiers in Neurology</i> , 2021, 12, 645298.	2.4	1
15	Longitudinal Analysis of Anti-cardiolipin and Anti- β 2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. <i>Frontiers in Medicine</i> , 2021, 8, 646846.	2.6	4
16	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1086-1093.	0.9	79
17	Interaction between the <i>STAT4</i> rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1183-1189.	0.9	10
18	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021, 8, e000463.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature. <i>Frontiers in Medicine</i> , 2021, 8, 661101.	2.6	3
20	Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity. <i>Lupus Science and Medicine</i> , 2021, 8, e000471.	2.7	4
21	POS0601â€¦DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 535.2-535.	0.9	1
22	Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 096120332110138.	1.6	5
23	Pentraxinâ€³ detected in human saliva shows limited correlation with biomarkers associated with systemic inflammation. <i>Apmis</i> , 2021, 129, 304-313.	2.0	2
24	POS1169â€¦IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 864-865.	0.9	1
25	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 688753.	4.8	12
26	Variants in BANK1 are associated with lupus nephritis of European ancestry. <i>Genes and Immunity</i> , 2021, 22, 194-202.	4.1	9
27	SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 724047.	4.8	13
28	Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 722118.	4.8	12
29	Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3820.	2.4	4
30	A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-3.	1.1	1
31	Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. <i>Frontiers in Immunology</i> , 2021, 12, 756941.	4.8	22
32	Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 722758.	2.6	7
33	Comment on â€œSystemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challengeâ€™: reply. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-2.	1.1	1
34	The Diagnostic Performance of an Extended Ultrasound Protocol in Patients With Clinically Suspected Giant Cell Arteritis. <i>Frontiers in Medicine</i> , 2021, 8, 807996.	2.6	15
35	Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1360-1368.	0.8	1
36	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , 2021, 7, e001987.	3.8	13

#	ARTICLE	IF	CITATIONS
37	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2021, 10, 5837.	2.4	27
38	Elevated free secretory component in early rheumatoid arthritis and prior to arthritis development in patients at increased risk. <i>Rheumatology</i> , 2020, 59, 979-987.	1.9	4
39	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 254-261.	0.9	30
40	Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives. <i>Clinical and Experimental Immunology</i> , 2020, 199, 143-149.	2.6	5
41	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
42	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. <i>Clinical and Experimental Immunology</i> , 2020, 199, 245-254.	2.6	29
43	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 363-369.	0.9	76
44	Neutrophil Extracellular Traps (NETs) in the Cerebrospinal Fluid Samples from Children and Adults with Central Nervous System Infections. <i>Cells</i> , 2020, 9, 43.	4.1	23
45	High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2020, 7, 581336.	2.6	11
46	P82...Anti-phospholipid antibodies and renal involvement are the main features associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus – a long-term longitudinal study in Southern Sweden. , 2020, , .		0
47	P137...De novo lupus nephritis during belimumab treatment. , 2020, , .		2
48	P23...Longitudinal antinuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of swedish cases with recent-onset disease. , 2020, , .		0
49	P91...The development and validation of a polygenic risk score for myocardial infarction in SLE. , 2020, , .		0
50	P86...The NCF1...339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. , 2020, , .		1
51	P89...Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2020, , .		0
52	P106...Pentameric, but not monomeric C-reactive protein, limits the snRNP-immune complex triggered type I interferon response: implications for lupus pathogenesis. , 2020, , .		0
53	P174...Extended arterial ultrasound revealing increased intima media thickness and relation to impaired microcirculation in systemic lupus erythematosus. , 2020, , .		0
54	P190...A simplified approach for patients with SLE to report disease activity using a revised version of the swedish systemic lupus activity questionnaire. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
55	O34â€¦Variants in <i>BANK1</i> are associated with lupus nephritis. , 2020, , .		0
56	P33â€¦Cytokine and autoantibody profiles during treatment with belimumab in patients with systemic lupus erythematosus. , 2020, , .		0
57	Synthesis of an Array of Triple-Helical Peptides from Type II Collagen for Multiplex Analysis of Autoantibodies in Rheumatoid Arthritis. ACS Chemical Biology, 2020, 15, 2605-2615.	3.4	7
58	Adverse Pregnancy Outcomes after Multi-Professional Follow-Up of Women with Systemic Lupus Erythematosus: An Observational Study from a Single Centre in Sweden. Journal of Clinical Medicine, 2020, 9, 2598.	2.4	12
59	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Frontiers in Immunology, 2020, 11, 578848.	4.8	11
60	Correspondence on â€œPerformance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicitiesâ€™. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219296.	0.9	1
61	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2020, 21, 3463.	4.1	26
62	Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus, 2020, 29, 625-630.	1.6	9
63	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. Seminars in Arthritis and Rheumatism, 2020, 50, 1387-1393.	3.4	16
64	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Frontiers in Medicine, 2020, 7, 316.	2.6	50
65	Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. Clinical and Experimental Immunology, 2020, 203, 22-31.	2.6	11
66	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. Frontiers in Immunology, 2020, 11, 622326.	4.8	26
67	Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels. Frontiers in Immunology, 2020, 11, 607166.	4.8	8
68	AB0321â€¦EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1459.1-1459.	0.9	0
69	AB0400â€¦PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSUS RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS. Annals of the Rheumatic Diseases, 2020, 79, 1499.2-1500.	0.9	0
70	Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome. Frontiers in Immunology, 2019, 10, 1686.	4.8	39
71	Low Production of Reactive Oxygen Species Drives Systemic Lupus Erythematosus. Trends in Molecular Medicine, 2019, 25, 826-835.	6.7	22
72	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. Lupus, 2019, 28, 1261-1272.	1.6	22

#	ARTICLE	IF	CITATIONS
73	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1363-1370.	0.9	60
74	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
75	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. <i>Human Genetics</i> , 2019, 138, 141-150.	3.8	63
76	The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable. <i>Lupus</i> , 2019, 28, 778-782.	1.6	52
77	Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. <i>Frontiers in Pharmacology</i> , 2019, 10, 82.	3.5	40
78	SAT0209...A SIMPLIFIED APPROACH FOR SLE PATIENTS TO REPORT DISEASE ACTIVITY USING A REVISED VERSION OF THE SWEDISH SYSTEMIC LUPUS ACTIVITY QUESTIONNAIRE. , 2019, , .		0
79	207...A high genetic risk score is associated with early disease onset, organ damage and decreased survival in systemic lupus erythematosus. , 2019, , .		1
80	12...Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2019, , .		0
81	264...Damage accrual in swedish systemic lupus erythematosus: secondary sjögrens syndrome is among the factors associated with increased risk. , 2019, , .		0
82	43...The diagnostic accuracy of the 2012 SLICC and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification is comparable. , 2019, , .		0
83	96...Cerebral hemodynamics and microcirculatory function in Swedish patients with systemic lupus erythematosus. , 2019, , .		0
84	Sex differences in clinical presentation of systemic lupus erythematosus. <i>Biology of Sex Differences</i> , 2019, 10, 60.	4.1	55
85	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019, 21, 259.	3.5	16
86	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. <i>European Journal of Human Genetics</i> , 2019, 27, 432-441.	2.8	12
87	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 320-327.	0.9	50
88	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1063-1069.	0.9	41
89	Uptake of rheumatology biosimilars in the absence of forced switching. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 499-504.	3.1	12
90	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 736-743.	0.9	135

#	ARTICLE	IF	CITATIONS
91	Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). <i>Rheumatology</i> , 2018, 57, 1400-1407.	1.9	39
92	Response to: "Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?" by Bruzzese and Zullo. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e72-e72.	0.9	0
93	S4D:5...Targeted next-generation sequencing suggests novel risk loci in juvenile onset systemic lupus erythematosus. , 2018, , .		2
94	Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	2.2	13
95	Active NET formation in Libman-Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. <i>Autoimmunity</i> , 2018, 51, 310-318.	2.6	11
96	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018, 194, 27-38.	2.6	16
97	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. <i>Journal of Immunological Methods</i> , 2018, 459, 11-19.	1.4	64
98	Smoking reduces the efficacy of belimumab in mucocutaneous lupus. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 911-920.	3.1	21
99	OP0362...Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. , 2018, , .		1
100	THU0196...Do contextual factors influence survival on drug of biosimilars in clinical practice?. , 2018, , .		0
101	Cervical neoplasia in systemic lupus erythematosus: a nationwide study. <i>Rheumatology</i> , 2017, 56, kew459.	1.9	19
102	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 343-351.	5.8	80
103	Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. <i>Lupus</i> , 2017, 26, 1333-1338.	1.6	25
104	Interferon- γ coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 <i>in vitro</i> . <i>Clinical and Experimental Immunology</i> , 2017, 189, 83-91.	2.6	17
105	P1_144 Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden. <i>Rheumatology</i> , 2017, 56, iii88-iii88.	1.9	0
106	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1544-1549.	0.9	86
107	Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. <i>Clinical and Experimental Immunology</i> , 2017, 189, 372-382.	2.6	26
108	Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox. <i>Arthritis and Rheumatology</i> , 2017, 69, 1707-1709.	5.6	1

#	ARTICLE	IF	CITATIONS
109	A single nucleotide polymorphism in the <i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1607-1613.	0.9	103
110	103...Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. , 2017, , .		0
111	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000225.	2.7	18
112	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	12.8	314
113	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. <i>Scientific Reports</i> , 2017, 7, 6236.	3.3	54
114	THU0652...Assessment of biosimilars using real world data: the complexity of choosing a comparator and understanding uptake. , 2017, , .		0
115	THU0663...Serum galectin-3 binding protein is a novel predictor of venous thromboembolism in patients with systemic lupus erythematosus (SLE). , 2017, , .		0
116	SAT0233...High anti-dsDNA content in sle immune complexes is associated with clinical remission following belimumab treatment. , 2017, , .		0
117	Case definitions in Swedish register data to identify systemic lupus erythematosus. <i>BMJ Open</i> , 2016, 6, e007769.	1.9	39
118	THU0345...Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and Î²2-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 312.1-312.	0.9	0
119	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. <i>Arthritis Research and Therapy</i> , 2016, 18, 289.	3.5	43
120	Long-term outcomes of destructive seronegative (rheumatoid) arthritis â€“ description of four clinical cases. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 246.	1.9	13
121	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Populationâ€Based Study of Maternal and Fetal Outcomes in SLE and Preâ€SLE. <i>Arthritis Care and Research</i> , 2016, 68, 988-994.	3.4	54
122	Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. <i>Cell Reports</i> , 2016, 16, 2928-2939.	6.4	38
123	OP0189...Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 128.2-128.	0.9	0
124	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. <i>Lupus</i> , 2016, 25, 864-872.	1.6	26
125	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 684-690.	3.4	23
126	Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells. <i>Journal of Virology</i> , 2016, 90, 4939-4950.	3.4	15

#	ARTICLE	IF	CITATIONS
127	Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis. <i>PLoS ONE</i> , 2016, 11, e0165373.	2.5	60
128	Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 338.	3.5	27
129	Soluble urokinase plasminogen activator receptorâ€™A valuable biomarker in systemic lupus erythematosus?. <i>Clinica Chimica Acta</i> , 2015, 444, 234-241.	1.1	27
130	Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. <i>Journal of Rheumatology</i> , 2015, 42, 817-825.	2.0	57
131	Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. <i>Arthritis Research and Therapy</i> , 2015, 17, 3.	3.5	84
132	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. <i>Translational Research</i> , 2015, 165, 658-666.	5.0	28
133	Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 337-339.	1.1	3
134	Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 188.	1.9	43
135	Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 569-581.	1.6	64
136	Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 265-70.	1.1	2
137	No Evidence of Pathogenic Involvement of Cathelicidins in Patient Cohorts and Mouse Models of Lupus and Arthritis. <i>PLoS ONE</i> , 2014, 9, e115474.	2.5	45
138	Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?. <i>Arthritis Care and Research</i> , 2014, 66, 1710-1717.	3.4	26
139	Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. <i>Nephrology Dialysis Transplantation</i> , 2014, 30 Suppl 1, i23-30.	0.7	8
140	Complement Opsonization of HIV-1 Results in Decreased Antiviral and Inflammatory Responses in Immature Dendritic Cells via CR3. <i>Journal of Immunology</i> , 2014, 193, 4590-4601.	0.8	44
141	Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 428-430.	1.1	27
142	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , 2014, 60, 1259-1267.	3.7	28
143	Association of Serum Câ€™Reactive Protein Levels With Lupus Disease Activity in the Absence of Measurable Interferonâ€™± and a Câ€™Reactive Protein Gene Variant. <i>Arthritis and Rheumatology</i> , 2014, 66, 1568-1573.	5.6	30
144	A3.7â€™...No evidence of cathelicidin being involved in the pathogenesis of lupus and arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A44.2-A45.	0.9	0

#	ARTICLE	IF	CITATIONS
145	THU0042...Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191.1-191.	0.9	0
146	FRI0172...Utility of Swedish Register Data in Classifying Systemic Lupus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 444.2-444.	0.9	0
147	Association of Genes in the <sc>NF</sc> Pathway with Antibody-Positive Primary Sjögren's Syndrome. <i>Scandinavian Journal of Immunology</i> , 2013, 78, 447-454.	2.7	45
148	Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. <i>Translational Research</i> , 2013, 162, 287-296.	5.0	43
149	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. <i>Autoimmunity</i> , 2013, 46, 205-214.	2.6	35
150	Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. <i>BMJ Open</i> , 2013, 3, e003608.	1.9	44
151	Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility. <i>Genes and Immunity</i> , 2013, 14, 217-222.	4.1	28
152	Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. <i>European Journal of Human Genetics</i> , 2013, 21, 994-999.	2.8	90
153	Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis. <i>PLoS ONE</i> , 2013, 8, e84450.	2.5	88
154	Association between genetic variants in the tumour necrosis factor/lymphotoxin 1/lymphotoxin 2 locus and primary Sjögren's syndrome in Scandinavian samples. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 981-988.	0.9	47
155	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. <i>Human Immunology</i> , 2012, 73, 382-388.	2.4	25
156	Common Genetic Variations in the NALP3 Inflammasome Are Associated with Delayed Apoptosis of Human Neutrophils. <i>PLoS ONE</i> , 2012, 7, e31326.	2.5	37
157	Resistin is Associated with Breach of Tolerance and Anti-nuclear Antibodies in Patients with Hepatobiliary Inflammation. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 463-470.	2.7	13
158	Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. <i>Genes and Immunity</i> , 2011, 12, 100-109.	4.1	113
159	Beware of Antibodies to Dietary Proteins in "Antigen-specific" Immunoassays! Falsely Positive Anticytokine Antibody Tests Due to Reactivity with Bovine Serum Albumin in Rheumatoid Arthritis (The Tj ETQq1 1207843146gBT /Ove		
160	Dr. Skogh, <i>et al,</i> reply. <i>Journal of Rheumatology</i> , 2009, 36, 1834-1834.	2.0	0
161	Interferon-1 mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares?. <i>Arthritis and Rheumatism</i> , 2009, 60, 3755-3760.	6.7	78
162	Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2009, 400, 128-131.	1.1	17

#	ARTICLE	IF	CITATIONS
163	Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R188.	3.5	39
164	C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. <i>Immunology and Cell Biology</i> , 2008, 86, 466-474.	2.3	20
165	Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 1994-2000.	2.0	37
166	Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. <i>Biochemical and Biophysical Research Communications</i> , 2007, 352, 251-258.	2.1	35
167	Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. <i>Clinica Chimica Acta</i> , 2007, 378, 13-23.	1.1	48
168	Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. <i>Clinical and Experimental Immunology</i> , 2007, 147, 513-520.	2.6	38
169	Tu-P10:452 C-reactive protein inhibit complement-mediated platelet activation suggesting a protective role in atherogenesis. <i>Atherosclerosis Supplements</i> , 2006, 7, 284.	1.2	0
170	Anti-CRP Autoantibody Levels Correlate with Disease Activity in Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 65-66.	3.4	6
171	CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , 2005, 1, 81-89.	0.8	7
172	Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. <i>Arthritis Research</i> , 2004, 6, R87.	2.0	82
173	Reduced anti-TNF α autoantibody levels coincide with flare in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2004, 22, 315-323.	6.5	39
174	Autoantibodies to C-reactive Protein is a Common Finding in SLE, but not in Primary Sjögren's Syndrome, Rheumatoid Arthritis or Inflammatory Bowel Disease. <i>Journal of Autoimmunity</i> , 2002, 19, 155-160.	6.5	58
175	Affected Microcirculation and Vascular Hemodynamics in Takayasu Arteritis. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	2